p16蛋白在宫颈癌前病变及宫颈癌筛查中的研究进展  

Research progress of p16 protein in the screening of cervical precancerous lesions and cervical cancer

作　　者：胡芬娜[1] 底姣阳 张三元[1] 

机构地区：[1]山西医科大学第一医院妇科,太原030000

出　　处：《中华妇幼临床医学杂志（电子版）》2017年第1期112-115,共4页Chinese Journal of Obstetrics & Gynecology and Pediatrics(Electronic Edition)

基　　金：山西省科技攻关项目(20120313019-3)~~

摘　　要：宫颈癌是全球女性最常见的恶性肿瘤之一,近年其发病率在世界范围内呈逐年上升趋势,对女性的健康和生命造成了极大的威胁,因此宫颈癌前病变的早期筛查、早期诊断、早期治疗是目前研究的重点和热点之一。宫颈癌前病变过程中可能出现蛋白分子水平的异常,如p16蛋白、L1壳蛋白等,这些蛋白分子可作为有效生物标志物进一步完善宫颈癌筛查方式,提高宫颈癌前病变的检出率,从而降低宫颈癌的发病率和病死率。笔者拟对p16蛋白在宫颈癌前病变及宫颈癌筛查中的研究进展进行综述,为临床医师制定合理治疗方案提供参考,旨在提高宫颈癌患者的生存率及生存质量。Cervical cancer is one of the most common malignant tumors of women around the world in recent years. The incidence rate of cervical cancer in the world is rising, and cervical cancer has caused great threat to women＇s health and lives. Therefore, early screening, diagnosis and treatment of cervical lesions are important and have been one of the researches hot spot. Abnormal levels of proteins, such as p16 protein, L1 capsid protein, may occur during cervical lesions. These proteins can be used as effective biomarkers to improve cancer screening methods and the detection rate of precancerous lesions of cervix uterus, ultimately, to reduce the incidence and mortality of cervical cancer. This article aims to explore the value of p16 protein in the screening and prognosis of cervical cancer, provide reasonable treatment scheme for clinicians, and ultimately improve survival rates and quality of life of cancer patients.

关 键 词：宫颈肿瘤 P16蛋白 筛查 预后 

分 类 号：R737.33[医药卫生—肿瘤]